

COMPLICATIONS AND THEIR MANAGEMENT IN AESTHETIC DERMATOLOGY

Magdolna Gaál M.D., Ph.D.

Aesthetic dermatologist, aesthetic trainer



21st Edition of Euroderm Excellence
Training Program

November 12-15, 2024
Budapest, Hungary



Excellence in dermatological
diagnostics, differential
diagnostics and therapy


MINIMAL INVASIVE AESTHETIC PROCEDURES

- Safety first! Be aware of possible adverse events, do everything to avoid them!
 - botulinum toxin treatment: storage, dilution, dosage, placement
 - precise planning, precise injections
- Reveal patients' expectations, treatment options, achievable aesthetic outcome
- Photo, short video
- Informed consent form with every possible side effects or adverse reactions
- Follow up visit if necessary, in case of any complaint, personal check up

BOTULINUM TOXIN TREATMENT OF GLABELLAR LINES

- target muscles:
- procerus muscle
- corrugator supercilii muscle
- orbicularis oculi muscle
- depressor supercilii muscle


- ABO: 3-7 x 5-15 DU, 30-80 DU
- ONA: 3-7 x 2-4 BU, 8-40 BU



SmPC Azzalure/Dysport®

BOTULINUM TOXIN TREATMENT OF GLABELLAR LINES: TOXIN SIDE EFFECTS TO AVOID

- descent of the medial part of the eyebrow (pseudo-mephisto sign)
 - toxin effect on the lower fibers of frontal muscle (injection too superficial or above the corrugator)
- blepharoptosis (ptosis of the upper eyelid)
 - toxin effect on levator palpebrae muscle (injection too close to the orbital rim or deep to the bone, under the muscle)
 - anatomical reasons
 - overdilution, too much volume, overdose
 - previously existing weakness of levator palpebrae muscle
 - resolves spontaneously in 1-6 weeks
 - IOPIDINE (apraclonidin) ocular drops, **open eye technique**
- PREVENTION:
 - avoiding overdosage, overdilution, precise injection points,
 - avoid massage for 1 week after injection
 - 3-point injection (Cotofana 2021)



Tremaine A. M. Clin Cosmet Investig Dermatol. 2010; 3: 15-23.
Redaelli A. J Cosmet Laser Ther. 2003 Dec;5(3-4):220-2.
King M. J Clin Aesthet Dermatol. 2016 Dec;9(12):E1-E4.


EYELID PTOSIS AFTER
BOTULINUM TOXIN
TREATMENT OF THE
GLABELLA



one week after botulinum
toxin treatment ,
apraclonidine eyedrop
started, temporary
improvement




ten days after the botulinum toxin
treatment a respiratory illness started,
ptosis increased.



after using open eye technique

BOTULINUM TOXIN TREATMENT OF GLABELLAR LINES: MINIMALIZATION OF THE RISK OF TOXIN SIDE EFFECTS



3-POINT TECHNIQUE


BOTULINUM TOXIN TREATMENT OF GLABELLAR LINES: TOXIN SIDE EFFECTS TO AVOID

- periorbital oedema
 - lymphatic stasis due to the relaxation of orbicularis oculi muscle

PREVENTION:

lower doses

- grotesk elevation of eyebrows ("Mephisto sign"), can be corrected



Tremaine A. M. Clin Cosmet Investig Dermatol. 2010; 3: 15–23.

Redaelli A. J Cosmet Laser Ther. 2003 Dec;5(3-4):220-2.

King M. J Clin Aesthet Dermatol. 2016 Dec;9(12):E1-E4.

BOTULINUM TOXIN TREATMENT OF CROW'S FEET

m. orbicularis oculi




- target muscle: orbicularis oculi muscle
- superficial injections
- eyebrow elevation is possible

- ABO: 2-3x5-15 DU/side
- ONA: 1-5x1-4 BU/side



BOTULINUM TOXIN TREATMENT OF CROW'S FEET: TOXIN SIDE EFFECTS TO AVOID

- altered smiling, asymmetric smile
 - cause: the lowest injection reaches the zygomatic minor and major muscles
 - prevention: superficial injection, not too low position, smaller dose to the lowest point
- periorbital oedema
 - prevention: avoid large doses
 - avoid massage for one week!




Kim B.W. et al. Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients. *J Dermatolog Treat.* 2014 Aug; 25(4):331-6
Klein A.W. Complications with the use of botulinum toxin. *Dermatol Clin* 2004; 22:197-205.
Chang Y.S. *Medicine (Baltimore)*. Nonallergic Eyelid Edema After Botulinum Toxin Type A Injection. *Case Report and Review of Literature. Medicine* 2015 Sep; 94(38): e1610.

BOTULINUM TOXIN TREATMENT OF THE FOREHEAD

target muscle: frontal muscle

- Be aware of the interaction with procerus muscle, corrugators, orbicularis oculi muscle
- eyebrow position/shape is very important, there is no other muscle which elevate the eyebrows



MOVEMENT OF THE FOREHEAD DURING MAXIMAL EYEBROW ELEVATION




- **Bimodal movement of the forehead**
- **szemöldök emelkedése, a hajvonal lefelé mozdulása**

nem mozgó horizontális vonal, ahol a két mozgás találkozik: line of convergence (C-line), szemöldök felett 3-4 cm-rel

átlagosan a második horizontális ránc vonalában mindkét nemnél, a szemöldök felett 61 ± 10 %-nál a homlok teljes magasságából

toxin adása a C-vonal felett csökkenti a szemöldök leereszkedésének veszélyét



INTRADERMAL INJECTIONS IN THE LOWER THIRD OF FOREHEAD
5X1 U ABOBOTULINUM TOXIN



BOTULINUM TOXIN TREATMENT OF THE FOREHEAD (ABO-BONT-A)



before treatment at maximal eyebrow lift



two weeks after treatment at maximal eyebrow lift

SHORT FOREHEAD, STRONG FRONTALIS MUSCLE


before treatment



before treatment at maximal eyebrow lift



two weeks after treatment



two weeks after treatment at maximal eyebrow lift



BOTULINUM TOXIN TREATMENT OF THE GLABELLA IN MEN


- 7-point technique (avoiding Mephisto effect)



Figure 1. Thirty-six-year-old man at maximal brow elevation (A) treated with BTX by an outside practitioner (dose unknown), presumably in a “V-shape” glabella pattern plus medial frontalis; (B) 9 months after, no BTX, immediately before BTX treatment of procerus, corrugator, and frontalis muscles; (C) 2 weeks after 80 U BTX treatment. BTX, botulinum toxin.

BOTULINUM TOXIN TREATMENT OF THE GLABELLA IN MEN

before the first treatment



two weeks after Abo-BONT-A
treatment



BOTULINUM TOXIN TREATMENT OF THE GLABELLA IN MEN

before the first treatment



two weeks after Abo-BONT-A treatment



- role of the upper fibers of orbicularis oculi muscle in frowning and producing glabellar wrinkles

BOTULINUM TOXIN TREATMENT OF THE GLABELLA IN MEN



before the first treatment



four month after the second treatment

before ABO-BontA treatment



four month after ABO-BontA treatment



GLABELLA AND FOREHEAD WITHOUT MUSCLE CONTRACTION
AFTER REPEATED TREATMENTS



2019



2020

2021



2023



FILLER COMPLICATIONS

- ecchymosis/bruising, pain
- oedema, erythema
- type I (immediate) allergy
- inappropriate filler position
- scar formation (rarity)
- infection
- granulomatous reaction (delayed type immune reaction)
- peripheral nerve damage
- vascular occlusion (embolisation or compression?)
 - tissue necrosis
 - cerebrovascular insult
 - blindness

Classification of Soft-Tissue Filler Complications by Onset of Adverse Event

Early reactions

Vascular infarction/soft-tissue necrosis

Inflammatory reactions (acute/chronic)

Infection

Allergic reactions/ hypersensitivity

Injection-related events

Pain

Ecchymosis

Erythema

Bruising

Bleeding

Inappropriate/superficial placement

Distant spread

Late reactions

Inflammatory reactions (acute/chronic)

Infection

Granuloma (typically chronic)

Differential diagnosis

Nodules

Dyspigmentation

Displacement of hyaluronic acid filler material

INAPPROPRIATE FILLER POSITION



INAPPROPRIATE FILLER POSITION: TREATMENT WITH HYALURONIDASE



INAPPROPRIATE FILLER PLACEMENT



INFECTION, BIOFILM FORMATION



GRANULOMATOUS REACTION



GRANULOMATOUS REACTION

- 15 years after Dermalive permanent filler treatment



SIGNS OF VASCULAR COMPROMISE DUE TO FILLER INJECTION

arterial occlusion

- pain immediately or within a few hours
- pain not on the site of injection, but on the site of embolus
- sudden whitening of the skin, then cutis marmorata, later livedo reticularis, purple discoloration
- "paupe hat sign": whitening of the white lip, nose, glabella
- Branches of the ophthalmic artery: sudden vision loss, pain, ophthalmoplegia, ptosis



veins

- milder symptoms, thrombophlebitis, skin is getting darker, oedema, milder pain

Eckart Haneke, J Cutan Aesthet 2015, Glynis Ablon, Plast Reconstr Surg, 2016
Jack F Scheuer et al Plast Reconstr Surg, 2017, Beleznay et al, Aesthet Surg, 2019

Lamilla, DeLorenzi, Karpova, Rzany, Trévidic:
Anatomy and filler complications

ARTERIAL OCCLUSION

- pallor instantly
- livedo reticularis rapidly and last 24-36 h



ARTERIAL OCCLUSION

PROLONGED
CAPILLARY REFILL
TIME (CRT)



ARTERIAL OCCLUSION

- pustule formation 72 hours after procedure
- coagulation
- soft tissue necrosis days or weeks later
- eschar and eventually scar formation days after procedure
- reperfusion injury



FACIAL AREAS AND ASSOCIATED RISK LEVELS



RISK ASSESSMENT	AREAS OF INJECTION
Very High	Glabella, nose and forehead
High	Temples, nasolabial folds, tear troughs, peri-orbital, medial cheek (between mid-papillary line and side of nose)
Moderate	Lips, perioral region, anterior cheek (between a vertical line through the lateral canthus and mid-pupillary line)
Low	Jawline and marionette, lateral cheek (lateral to vertical line through lateral canthus), sub malar, preauricular, chin augmentation

VASCULAR COMPROMISE DUE TO FILLERS: PREVENTION

- detailed knowledge of facial anatomy, 3D!!! (THERE IS NO SAFE!)
- blunt tipped cannula in certain areas (22 G, 25 G)
- aspiration??
- product knowledge
- inject slowly at a low pressure
- small boluses, avoid large volume boluses
- continuous movement of the tip of the needle
- targeted digital pressure to compress vessels e.g. on the inferior-medial orbital rim and on the nose
- observe the patient (unexpected, unusual pain, skin reaction), communication
- extreme caution in case of previous trauma, surgical intervention

Glynis Ablon, *Plast Reconstr Surg*, 2016
Jack F Scheuer et al, *Plast Reconstr Surg*, 2017
Philipp-Dormston et al, *JEADV*, 2017
Pavivic et al, *Plast Reconstr Surg*, 2019
Urdiales-González, *Aesthetic Plast Surg*, 2018
Lee, King, *JCAD*, 2018, 2020
Murray et al, *CMAC, JCAD*, 2021

VASCULAR COMPROMISE DUE TO FILLERS: DIAGNOSIS, TREATMENT


RECOGNISE!!! CAPILLARY REFILL TIME! (less than 2 sec)

- diff.: bruising, herpes simplex virus infection, zoster

TREATMENT

- the injection should be stopped immediately
- observe CRT prior to treatment (both sides), video
- disinfect, mark the area
- hyaluronidase!!! (1500 U + 1 ML 0.9% NaCl or 1-2 % Lidocain treat the whole area)
- ultrasound targeted hyaluronidase injection
- massage, apply heat
- sublingval nitrate spray, nitrate skinpatch
- ASA 300 mg on the 1st day, then 75 mg daily
- in 15-20 min, reassess CRT, if > 3 sec, repeat hyaluronidase
- hyperbaric oxygen?
- wound management

The angiosome




Chnis Ablon, Plast Reconstr Surg, 2016
Jack F Scheuer et al, Plast Reconstr Surg, 2017
Philipp-Dormston et al, JEADV, 2017
Pavicic et al, Plast Reconstr Surg, 2019
Urdiales-González, Aesthetic Plast Surg, 2018
Lee, King, JCAD, 2018, 2020

Murray et al, CMAC, JCAD, 2021

Henderson et al, Plast Reconstr Surg Glob Open, 2018

VASCULAR COMPROMISE AFFECTING BRANCHES OF OPHTHALMIC ARTERY DUE TO FILLERS POSSIBLE SYMPTOMS

- sudden sharp headache, ocular pain
- unilateral (rarely bilateral) usually immediate vision loss
- nausea
- ophthalmoplegia
- ptosis
- strabism
- pupil abnormality
- enophthalmus
- skin reaction (43,8%)



Urdiales-Gálvez et al, 2018
Expert Consensus
K. Beleznyay et al, Aesth Surg J, 2019
Mccann, 2019
Kim et al, J Clin Aesthet Dermatol 2015
Chen et al, Facial Plast Surg, 2018
Lee, King, JCAD, 2018

VISION LOSS DUE TO FILLER PROCEDURE: ANATOMICAL AREAS WHERE THE FILLER WAS PLACED





Figure 1. Location of filler injection resulting in visual complication. The single black dot represents a case where the anatomic location of injection was not specified.

Rates of blindness relative to the anatomical zone injected

ANATOMICAL AREA	INCIDENCE 2015	INCIDENCE 2019
Nose	25.5%	56.3%
Glabella	38.3%	27.1%
Forehead	12.2 %	18.8%
Nasolabial fold	13.3%	14.6%

Murray et al, CMAC, JCAD, 2021


MECHANISM OF VISION LOSS



K. Belezny et al, Aesth Surg J, 2019

VISION LOSS SECONDARY TO COSMETIC FILLER INJECTIONS

An Aesthetic Complications Expert (ACE) Group Consensus Paper



- Ophthalmic artery occlusion (OAO)
- Generalized posterior ciliary artery occlusion with relative central retinal artery sparing (PCAO)
- Central retinal artery occlusion (CRAO)
- Branch retinal artery occlusion (BRAO)
- Anterior ischaemic optic neuropathy (AION)
- Posterior ischaemic optic neuropathy (PION).

- +/- ophthalmoplegia, +/- ptosis Walker, King, JCAD 2018

VISION LOSS: EMERGENCY INTERVENTIONS

IN OFFICE:

90 minutes, but the first 30 minutes are critical

- stop injecting immediately, don't panic
- alert the ophthalmological unit, ask for immediate transport
- lay down the patient, timolol ocular drops (1-2) only into the affected eye
- 300 mg ASA (continue for 1 week 75 mg daily)
- CO₂ rebreathing (rebreathing into a bag)
- sublingual nitrate spray
- vision check, pupil reaction analysis
- ocular massage (until the ophthalmologist doesn't recommend else (pressure for a few mm, 5 sec, then release for 10 sec, closed eyes)
- hyaluronidase? if there is skin reaction



OPHTHALMOLOGY

- 100 ml 20% mannitol inf.
- iv. acetazolamide 500 mg
- LMWH?, iv. steroid
- retinography
- retro-, or peribulbar hyaluronidase 1500 U, repeat
- anterior chamber paracentesis
- hyperbaric O₂ ??
- intraarterial thrombolysis is not effective!!

Urdiales-Gálvez et al, 2018 Expert Consensus

Beleznay et al, Aesth Surg J, 2019, M. King, L. Walker, JCAD, 2020

Mccann, 2019, Kim et al, J Clin Aesthet Dermatol 2015, Chen et al, Facial Plast Surg, 2018, Humzah et al, J Cosmet Dermatol, 2019

AESTHETIC INTERVENTIONAL INDUCED VISUAL LOSS CONSENSUS GROUP

Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss

[Lee Walker](#), BDS, MFDS, RCPSG, MJDF, RCS, ENG,²⁰ [Cormac Convery](#), MB ChB, MSc, MASLMS, [Emma Davies](#), RN, INP, [Gillian Murray](#), MPharm, PG Dip Clin Pharm, INP, and [Brittany Croasdeli](#), MS, FNP-BC, APRN CANS

[Author information](#) [Copyright and License information](#) [PMC Disclaimer](#)

CURRENT TREATMENT STRATEGIES	MODE OF ACTION	MECHANISM OF ACTION
Non-pharmacological		
Ocular massage	Dislodge	Repeated compression of the eyeball to dislodge blockage: a sudden drop in intraocular pressure (IOP) with release increases the retinal perfusion
Anterior chamber paracentesis	Reduce intraocular pressure	Extracting 0.1-0.2ml aqueous fluid via needle to reduce IOP and to allow an increase in perfusion pressure
Hyperbaric oxygen	Increase perfusion	Increase oxygen tension and oxygen delivery to ischaemic retinal tissue—involves intermittent inhalation of 100% oxygen under a pressure greater than 1 atm
CO2 rebreathing	Increase perfusion	Rebreathing into a bag produces both hypercapnia which is known to increase retinal blood flow and hypoxia which causes vasodilation. In addition, both hypercapnia and hypoxia can increase cardiac out-put and raise systemic arterial blood pressure, which in turn, increases ocular perfusion pressure.
Pharmacological		
Timolol drops	Reduction in intraocular pressure	Suppress aqueous humour formation, reduce IOP and increases perfusion
IV Mannitol, Acetazolamide	Reduce intraocular pressure	Medication used in glaucoma to reduce intraocular pressure
Aspirin	Prevents clot formation	Prevents platelet aggregation, allowing body to breakdown embolus element of blockage
Topical and systemic steroids	Reduce intraocular pressure	Reduction in vascular endothelial oedema
Sublingual isosorbide mononitrate	Increase perfusion	Causes a mild decrease in intraocular pressure along with corresponding dilation of retinal vasculature and increased perfusion in the retinal artery

EMERGENCY KIT

- hyaluronidase (> 3000 U)
- Tonogen/adrenaline
- ASA
- timolol 0.5% ocular drops
- IOPIDINE (apraclonidine) ocular drops (in case of ptosis due to botulinum toxin treatment)
- set for venal infusion, cristalloid
- nitrate sublingual spray/tab. /patch
- steroid, antihistamine
- warming package
- plastic or paper bag
- resuscitation masque
- needles, syringes (1 ml, 10 ml)
- check the kit every month



Humzah et al, J Cosmet Dermatol, 2019
AESTHETIC INTERVENTIONAL INDUCED VISUAL LOSS
CONSENSUS GROUP
Prado, Rodriguez-Feliz, Aest Plas Surg, 2017
Martyn King, J Clin Aesthet Dermatol, 2018

FILLERS: PREVENTION OF COMPLICATIONS

- deep understanding of 3D anatomy
- check patients medical history
- patient selection, indication
- technique: correct plane, inject slowly, blunt tip cannula in some anatomical region (25 G, 22G)
- pay attention to the patients' reactions, skin, pain
- product selection depending on the indication (rheological properties, cutting edge quality), correct amount of product

LIPS APPROPRIATE TO AGE?



BEAUTY = WRINKLE-FREE?





<http://www.youngeryou.com.au/news-features/celebrities/>
<http://www.msnbc.msn.com/id/34462651/>



NON DYNAMIC
FILLER IN A
DYNAMIC AREA:
UNNATURAL
APPEARANCE

AGE-APPROPRIATE HARMONY

